Method for the detection of infective viral particles of SARS-COV2 (COVID-19)

  • From Spain
  • Responsive
  • Patents for licensing

Summary of the technology

The SARS-CoV-2 detection technique allows us to know the genetic material of the virus, that is, whether or not it is present in the body. The microbiologist David Rodríguez Lázaro, from the University of Burgos, has developed a new system that makes it possible to know if it has infective capacity and thus eliminate doubts about unclear results, putting as an example those positives that are maintained for a long time, which do not it is consistent with the infectious period. It is a very valuable tool to help make medical decisions for patients who are admitted, especially at times of an increase in infections, or to facilitate discharges to join the job.


Details of the Technology Offer

New and innovative aspects

The RT-qPCR technique amplifies the RNA present in the sample taken from the patient, but it amplifies all the RNA present, both that found within intact/infective viral particles, and that found free in the sample, from particles virus damaged/non-infective. This generates false positive results in the diagnosis of some patients. The invention allows, by pretreatment, that the RT-qPCR is able to detect and amplify only intact/infective virus particles.

Main advantages of its use

The advantage of the invention is that, once the previous treatment that is the object of the invention has been carried out, it allows the conventional RT-qPCR technique, used in the usual way (without subsequent modifications, and without the need for new equipment or methodologies) be able to unequivocally detect the presence of intact / infective particles of the SARS-COV2 virus.


The invention consists of a treatment of nasopharyngeal swab samples taken from patients for the diagnosis of disease caused by coronavirus (SARS-COV2). The treatment consists of adding to the sample some ¨colourants¨ or PCR viability markers, which bind irreversibly to the free RNA present in the sample and are able to inhibit subsequent PCR. This means that the free RNA present in the samples (from damaged / non-infective viral particles, therefore it is free in the sample) cannot be amplified or detected in the subsequent PCR, thus avoiding false positive diagnoses.


Clinical diagnosis of coronavirus disease (SARS-COV2)

Intellectual property status

Protected by patent P202130632

Current development status

Validation tests have been carried out.

Desired business relationship

Commercial Agreement, License Agreement, Technical Cooperation: further development; Technical Cooperation: testing new applications; Technical Cooperation: adaptation to specific needs.

Intellectual property status

Related Keywords

  • Diagnostics, Diagnosis
  • Virus, Virology / Antibiotics / Bacteriology
  • Protecting Man and Environment
  • Social and Economics concerns
  • Infectious Diseases
  • Diagnostic services
  • Industrial Products
  • Other
  • Covid-19
  • PCR
  • sars-cov-2
  • rt-qpcr
  • viability markers
  • clinical diagnosis
  • infective virus particles
  • nasopharyngeal swab
  • discrimination of infective virus particles


The aim of the The Technology Transfer Office (TTO) of the Univesidad de Burgos is to promote Innovation technology through the reseach results transfer and the conexions between the University and the new needs and requirements of the society - we are the link between the University and the Industry. Contact person: José Manuel López (


Never miss an update from UNIVERSIDAD DE BURGOS

Create your free account to connect with UNIVERSIDAD DE BURGOS and thousands of other innovative organizations and professionals worldwide


Send a request for information

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support